Serum KL-6 levels as a biomarker of lung injury in respiratory syncytial virus bronchiolitis.
To evaluate whether KL-6 concentration is a useful biomarker of the severity of respiratory syncytial virus (RSV) bronchiolitis, we determined KL-6 concentrations in patients with RSV bronchiolitis with or without chronic heart disease (CHD). We enrolled 52 patients who had been diagnosed with RSV bronchiolitis and required admission to the hospital at the Department of Pediatrics of Fukushima Medical University School of Medicine from 2004 to 2005. These patients were divided into two groups: Group 1 consisted of patients without any underlying disease, and Group 2 consisted of patients with CHD. These patients were assigned to three categories. Stage A consisted of patients without oxygen dosage, stage B of patients who required oxygen dosage, and stage C of patients required artificial respiration. We evaluated baseline characteristics, clinical features, and serum KL-6 concentration in Group 1, Group 2, and a control group (healthy infants without infection). Mean serum KL-6 concentrations in patients with RSV bronchiolitis were higher than those in the control group (471.8 +/- 236.9 and 127.1 +/- 69.1 U/ml, respectively). Mean serum KL-6 concentration was higher in Group 2 than in Group 1 (692.8 +/- 313.1 and 390.4 +/- 132.7 U/ml, respectively). Mean serum KL-6 concentrations were higher in stage C than in stages A and B, and mean serum KL-6 concentrations were higher in stage B than in stage A. These findings suggest that serum KL-6 is associated with the severity of RSV bronchiolitis and that it may be a useful biomarker for the severity of RSV bronchiolitis.
Kawasaki
Yukihiko
Y
Department of Pediatrics, Fukushima Medical University School of Medicine, Hikariga-oka, Fukushima City, Fukushima, Japan. kyuki@fmu.ac.jp
Aoyagi
Yoshimichi
Y
Abe
Yusaku
Y
Go
Hayato
H
Imamura
Takashi
T
Kaneko
Mari
M
Ito
Masaki
M
Katayose
Masahiko
M
Hashimoto
Koichi
K
Hosoya
Mitsuaki
M
D015415:Biomarkers / Q000097:blood; D001990:Bronchiolitis, Viral / Q000097:blood* / Q000150:complications / Q000473:pathology* / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D005260:Female; D006331:Heart Diseases / Q000150:complications; D006801:Humans; D007223:Infant; D055370:Lung Injury / Q000097:blood* / Q000209:etiology / Q000473:pathology* / Q000821:virology; D008297:Male; D018396:Mucin-1 / Q000097:blood*; D010102:Oxygen Inhalation Therapy; D018357:Respiratory Syncytial Virus Infections / Q000097:blood* / Q000150:complications / Q000473:pathology* / Q000628:therapy
D015415:Biomarkers; C060192:MUC1 protein, human; D018396:Mucin-1